Abstract:To retrospectively evaluate clinical and dosimetric factors associated with severe (grade≥3) radiation pneumonitis in patients after concurrent chemotherapy and intensity-modulated radiotherapy (IMRT). We retrospectively analyzed 94 locally advanced NSCLC patients treated with concurrent chemotherapy and IMRT between May 2005 and September 2006. Radiation pneumonitis was graded according to Common Terminology Criteria for Adverse Events version 3.0. The following clinical parameters were considered: gender, age, smoking and diabetes history, history of chronic obstructive pulmonary disease (COPD), induction chemotherapy, concurrent chemotherapy regimens, performance status and forced expiratory volume in 1 second (FEV1). Dosimetric factors including mean lung dose (Dmean), rV5-V60 relative volumes of lung receiving more than a threshold dose D of radiation (rVD), where values of D considered were 5°C 60 Gy in increments of 5 Gy), prescribed dose (63GY/35f/7w vs 60Gy/30f/6w), and normal tissue complication probability (NTCP) values were analysed. DVHs data and NTCP values were collected for both lungs considered as a parallel organ. Pearson Chi-Square test was performed to compare clinical parameters between patients who developed severe RP and those who did not. Univariate and multivariate logistic regression analyses were performed to evaluate data for association between clinical and dosimetric factors and severe RP. The study was approved by the institutional reviewboard. Of 94 patients, 11 (11.7%) develop severe (grade≥3) radiation pneumonitis; 6 (6.4%), grade 3; 2(2.1%), grade 4; and 3 (3.2%)grade 5. Univariate analyses show that Sex, age (≤60vs>60), smoking and diabetes history, induction chemotherapy, concurrent chemotherapy regimens, PS(≤70vs>70) and prescribed dose did not significantly differ between patients who developed severe RP and those who did not. However, NTCP, MLD, rV5-V60, COPD and FEV1 were associated with severe RP (p<0.05). In multivariate analysis, NTCP (p=0.001) and rV10(p=0.015) was the most significant factors associated with severe (grade≥3) radiation pneumonitis. The incidences of Grade≥3 pneumonitis in the group with NTCP>4.2% and NTCP <4.2% were 43.5% and 1.4%, respectively (p<0.01). The incidences of Grade≥3 pneumonitis in the group with rV10 <51.2% and rV10 >51.2% were 5.6% and 30.4%, respectively (p<0.01). NTCP and rV10 is useful indicator of risk for development of severe (grade≥3) radiation pneumonitis in NSCLC patients after concurrent chemotherapy and intensity -modulated radiotherapy (IMRT).

Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases

Immediate outcomes and toxicities of intensity modulated radiation therapy in the treatment of non-small cell lung cancer

Induction Immune Checkpoint Inhibitors and Chemotherapy for Patients with Stage III Non-Small Cell Lung Cancer: A Real-World Experience.

Risk Factors for Radiation Induced Lung Toxicity in Locally Advanced Non-Small Cell Lung Cancer Treated with Three-Dimensional Radiotherapy

Safety and Efficacy of Hypofractionated Radiotherapy and Concurrent Chemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer

The Impact of Radiation Induced Lymphopenia in the Prognosis of Head and Neck Cancer: A Systematic Review and Meta-Analysis

Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: the MD Anderson Experience

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

Preliminary Study of the Intensity Modulated Radiation Therapy for NSCLC

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial

Efficacy of the Smaller Target Volume for Stage III Non-Small Cell Lung Cancer Treated with Intensity-Modulated Radiotherapy.

Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer

Efficacy and Safety of Definitive Chemoradiotherapy with or Without Induction Immune Checkpoint Inhibitors in Patients with Stage III Non-Small Cell Lung Cancer

Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy

Preliminary Results about Application of Intensity-Modulated Radiotherapy to Reduce Prophylactic Radiation Dose in Limited-Stage Small Cell Lung Cancer

Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy with Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial.

Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis

P2-223: Analysis of Clinical and Dosimetric Factors Associated with Severe Radiation Pneumonitis in Locally Advanced Non–Small–Cell–Lung–Cancer Patients Treated with Concurrent Chemotherapy and Intensity–modulated Radiotherapy (IMRT)

Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease

Clinical results of carbon-ion radiotherapy for stage I non-small cell lung cancer with concomitant interstitial lung disease: a Japanese national registry study (J-CROS-LUNG)

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity